Literature DB >> 27165139

Evaluation of carcinoembryonic antigen (CEA) density as a prognostic factor for percutaneous ablation of pulmonary colorectal metastases.

Ya Ruth Huo1,2, Derek Glenn2,3, Winston Liauw2,4, Mark Power3, Jing Zhao1, David L Morris5,6.   

Abstract

OBJECTIVES: To evaluate the prognostic value of carcinoembryonic antigen (CEA) density and other clinicopathological factors for percutaneous ablation of pulmonary metastases from colorectal cancer.
METHODS: CEA density was calculated as: "absolute serum CEA pre-ablation/volume of all lung metastases [mm3]". Median CEA density was the cut-off for high and low groups. Cox-regression was used to determine prognostic factors for survival.
RESULTS: A total of 85 patients (102 ablation sessions) were followed for a median of 27 months. High CEA density was significantly associated with worse overall survival compared to low CEA density (adjusted HR: 2.12; 95 % CI: 1.22-3.70, p=0.002; median survival: 25.7 vs. 44.3 months). The interval between primary resection of the colorectal carcinoma and first ablation was also a prognostic factor, a duration >24 months being associated with better survival compared to a shorter interval (0-24 months) (adjusted HR: 0.55; 95 % CI: 0.31-0.98, p=0.04). Moreover, a disease-free interval >24 months was significantly associated with low CEA density compared to a shorter interval (0-24 months) (adjusted OR: 0.29; 95 % CI: 0.11-0.77, p=0.01).
CONCLUSIONS: Serum CEA density and interval between primary resection of a colorectal carcinoma and pulmonary ablation are independent prognostic factors for overall survival. In two patients with identical CEA serum levels, the patient with the lower/smaller pulmonary tumour load would have a worse prognosis than the one with the higher/larger pulmonary metastases. KEY POINTS: • CEA density is an independent prognostic factor for colorectal pulmonary metastases. • A lower CEA density is associated with better overall survival. • CEA may play a functional role in tumour progression. • High CEA density is associated with smaller tumours. • Interval between pulmonary ablation and primary colorectal carcinoma is a prognostic factor.

Entities:  

Keywords:  Carcinoembryonic antigen; Percutaneous ablation; Prognostic factor; Pulmonary colorectal metastases; Survival

Mesh:

Substances:

Year:  2016        PMID: 27165139     DOI: 10.1007/s00330-016-4352-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  36 in total

1.  Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer.

Authors:  K Kobayashi; M Kawamura; T Ishihara
Journal:  J Thorac Cardiovasc Surg       Date:  1999-12       Impact factor: 5.209

2.  PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer.

Authors:  Stavros Sfoungaristos; Petros Perimenis
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

3.  Radiofrequency ablation of concomitant and recurrent pulmonary metastases after surgery for colorectal liver metastases.

Authors:  Terence C Chua; Ihssan Al-Alem; Jing Zhao; Derek Glenn; Winston Liauw; David L Morris
Journal:  Ann Surg Oncol       Date:  2011-06-28       Impact factor: 5.344

4.  Prognostic impact of lymph node involvement in pulmonary metastases from colorectal cancer.

Authors:  Stefan Welter; Jan Jacobs; Thomas Krbek; Christoph Poettgen; Georgios Stamatis
Journal:  Eur J Cardiothorac Surg       Date:  2006-12-05       Impact factor: 4.191

5.  Prognostic factors in resection of pulmonary metastasis from colorectal cancer.

Authors:  I Watanabe; T Arai; M Ono; M Sugito; K Kawashima; M Ito; K Nagai; N Saito
Journal:  Br J Surg       Date:  2003-11       Impact factor: 6.939

6.  Carcinoembryonic antigen from human malignant melanoma cells. I. Production and shedding characteristics.

Authors:  A A Hakim; C M Siraki; C E Joseph
Journal:  Ann Immunol (Paris)       Date:  1983 Nov-Dec

7.  Outcome after radiofrequency ablation of sarcoma lung metastases.

Authors:  Claus Koelblinger; Sandra Strauss; Alice Gillams
Journal:  Cardiovasc Intervent Radiol       Date:  2013-05-14       Impact factor: 2.740

8.  Use of chemotherapy and radiofrequency ablation to treat colorectal cancer metastases: a retrospective review of The Ottawa Hospital Cancer Centre over 7 years.

Authors:  N Boame; G Gresham; D Jonker; G Martel; F Balaa; T Asmis
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

9.  Carcinoembryonic antigen functions as an accessory adhesion molecule mediating colon epithelial cell-collagen interactions.

Authors:  M Pignatelli; H Durbin; W F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

Review 10.  Local surgical, ablative, and radiation treatment of metastases.

Authors:  Robert D Timmerman; Costas S Bizekis; Harvey I Pass; Yuman Fong; Damian E Dupuy; Laura A Dawson; David Lu
Journal:  CA Cancer J Clin       Date:  2009-04-10       Impact factor: 508.702

View more
  2 in total

1.  The family of apoptosis-stimulating proteins of p53 is dysregulated in colorectal cancer patients.

Authors:  Libin Yin; Yuyang Lin; Xu Wang; Yanzhuo Su; Han Hu; Chao Li; Lei Wang; Yanfang Jiang
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

Review 2.  Up-to-date evidence on image-guided thermal ablation for metastatic lung tumors: a review.

Authors:  Yusuke Matsui; Koji Tomita; Mayu Uka; Noriyuki Umakoshi; Takahiro Kawabata; Kazuaki Munetomo; Shoma Nagata; Toshihiro Iguchi; Takao Hiraki
Journal:  Jpn J Radiol       Date:  2022-07-02       Impact factor: 2.701

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.